]>
IRCT20220818055740N2 IRCT 2022-09-27 Shahre-kord University of Medical Sciences Determination of the therapeutic efficacy of ginger in the treatment of migraine headaches Determination of the therapeutic efficacy of ginger in the treatment of migraine headaches 2019-06-29 anticipated 80 Complete https://irct.ir/trial/65453 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Diagnostic, Randomization description: The random allocation of the participants to the intervention and control groups will be done using random allocation software. Then, many envelopes will be prepared according to the number of participants in the study. Then, number 1 will be recorded on the first envelope, number 2 on the second envelope, and etc. The sequence of assignment of the participants will be determined by the software and each assignment will be put inside each envelope respectively. At the time of study , the specified envelope for each individual will be opened and the individual will be assigned to one of the intervention and control groups according to the option recorded inside the envelope, Blinding description: The single blindness of the study was performed in this process that at first the mentioned drugs received code without any labels and the patient selected one of the two drugs randomly. Then, the name of each person and the drug code provided to him registered by the secretary. Neither the patient nor the doctor was not aware of the type of medication. The name of each person and his drug was specified only during analyzing the data, and completed the patients' information profile by mentioning the name of the drug received by them. 3 Migraine. Intervention 1: The control group received 500 mg/day Depakene orally daily once for sixteen weeks mgmanufactured by Zintoma (Gol darou Co.). Intervention 2: Intervention group: The treatment group received two ginger capsules 250mg along with 500 mg/day Depakene manufactured by Zintoma (Gol darou Co.) orally for sixteen weeks. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information
public Nahid Jivad
Kashani Hospital, Shahrekord University of Medical Sciences, Parastar Street, Shahrekord
Shahrekord Iran (Islamic Republic of) 818718791 +98 38 3335 1031 jivad@skums.ac.ir Shahre-kord University of Medical Sciences scientific Nahid Jivad
Kashani Hospital of Shahrekord University of Medical Sciences, Parastar street, Shahrekord, Iran
Shahrekord Iran (Islamic Republic of) 8818718791 +98 38 3222 0016 jivad@skums.ac.ir Shahre-kord University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: Age between 18 to 65 years; history of migraine headache before performing the study based on IHS criteria; headache from moderate to severe less than six days by visual analogue score(Vas); absence of diseases such as liver, heart, active stomach ulcer, diabetes and renal failure. 18 years 65 years Both Exclusion criteria: Abnormal vital signs during the study;, new abnormal findings during CT scan; dissatisfaction patients to continue the study;, and observation of drug sensitivity. G43 Migraine Diagnosis Treatment - Drugs The control group received 500 mg/day Depakene orally daily once for sixteen weeks mgmanufactured by Zintoma (Gol darou Co.) Intervention group: The treatment group received two ginger capsules 250mg along with 500 mg/day Depakene manufactured by Zintoma (Gol darou Co.) orally for sixteen weeks. Migraine headache. Timepoint: One month after intervention. Method of measurement: VAS, PSQI, MIDAS questionnaires. Migraine headache. Timepoint: One month after intervention. Method of measurement: VAS, PSQI, MIDAS questionnaires. Shahre-kord University of Medical Sciences Approved 2019-08-23 Ethics committee of Shahrekord University of Medical Sciences Kashani Blvd, Shahrekord University of Medical Sciences, Shahrekord, Iran Shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)